Imipenem + CilastatinThird Party Manufacturing in India

Imipenem + Cilastatin works by pairing a broad-spectrum carbapenem antibiotic with a specific renal dehydropeptidase-I inhibitor. It inhibits bacterial cell wall assembly via imipenem while cilastatin blocks renal metabolism of the antibiotic to help the body maintain effective plasma drug levels. Unlike standalone carbapenems, this combination prevents the formation of nephrotoxic metabolites and ensures high urinary recovery. Quality control is maintained under primary CAS 74431-23-5. It is highly effective and well-tolerated.

Therapeutic Uses

• Polymicrobial Infections: First-line clinical treatment for severe, mixed aerobic-anaerobic intra-abdominal sepsis.
• Hospital Endocarditis: Indicated for complex endocardial infections involving multi-resistant bacterial pathogens.
• Neutropenic Fever: Deployed as an empirical monotherapy for febrile episodes in neutropenic oncology patients.

Why Manufacturers Choose Imipenem + Cilastatin

This combo is an essential component of clinical anti-infective portfolios for institutional healthcare bidding. Sourcing through Imipenem + Cilastatin third party manufacturing in India ensures corporate buyers receive high-quality sterile products at highly competitive costs. Our manufacturing partner facilities are fully integrated with modern sterile lines operating under WHO-GMP specifications. Complete documentation support is available to expedite global registration processes.